CRISPR Therapeutics AG (CRSP) Change in Cash (2015 - 2026)

CRISPR Therapeutics AG has disclosed Change in Cash across 12 years of filings, most recently posting $72.2 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $72.2 million, up 214.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.6 million (up 139.09% YoY), and the FY2025 annual result was $49.3 million, up 154.0% from the prior year.
• Change in Cash came in at $72.2 million for Q1 2026 at CRISPR Therapeutics AG, up from $61.1 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $317.9 million in Q1 2024 to a low of -$286.3 million in Q4 2022.
• The 5-year median for Change in Cash is -$2.7 million (2022), against an average of -$29.9 million.
• Across the five-year window, Change in Cash slumped 461.8% in 2022 and surged 3126.99% in 2023, its largest moves.
• CRISPR Therapeutics AG's Change in Cash stood at -$286.3 million in 2022, then jumped by 51.61% to -$138.5 million in 2023, then soared by 152.4% to $72.6 million in 2024, then dropped by 15.88% to $61.1 million in 2025, then advanced by 18.3% to $72.2 million in 2026.
• The last three Change in Cash figures came in at $72.2 million (Q1 2026), $61.1 million (Q4 2025), and $92.9 million (Q3 2025), per Business Quant data.